William P. Forbes

7.0k total citations · 2 hit papers
107 papers, 4.9k citations indexed

About

William P. Forbes is a scholar working on Epidemiology, Surgery and Gastroenterology. According to data from OpenAlex, William P. Forbes has authored 107 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Epidemiology, 27 papers in Surgery and 26 papers in Gastroenterology. Recurrent topics in William P. Forbes's work include Inflammatory Bowel Disease (24 papers), Gastrointestinal motility and disorders (21 papers) and Microscopic Colitis (19 papers). William P. Forbes is often cited by papers focused on Inflammatory Bowel Disease (24 papers), Gastrointestinal motility and disorders (21 papers) and Microscopic Colitis (19 papers). William P. Forbes collaborates with scholars based in United States, Canada and Spain. William P. Forbes's co-authors include Enoch Bortey, Audrey L. Shaw, Anthony Lembo, Mark Pimentel, Bruce S. Cutler, Salam Zakko, Craig Paterson, Steven L. Bramer, Peter Zhang and William D. Chey and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

William P. Forbes

103 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rifaximin Treatment in Hepatic Encephalopathy

2010 848 citations Fred Poordad, Samuel H. Sigal et al. profile →
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

2011 720 citations Salam Zakko, Jing Yu et al. profile →

Peers

Countries citing papers authored by William P. Forbes

Since Specialization

Citations

This map shows the geographic impact of William P. Forbes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William P. Forbes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William P. Forbes more than expected).

Fields of papers citing papers by William P. Forbes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William P. Forbes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William P. Forbes. The network helps show where William P. Forbes may publish in the future.

Co-authorship network of co-authors of William P. Forbes

This figure shows the co-authorship network connecting the top 25 collaborators of William P. Forbes. A scholar is included among the top collaborators of William P. Forbes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William P. Forbes. William P. Forbes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	OP011. Budesonide MMX(R) 9 mg for Inducing Remission in Patients with Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled with Oral 5-ASAs 2015 ·Journal of Crohn s and Colitis ·David T. Rubin, Russell D. Cohen, William J. Sandborn, Gary R. Lichtenstein, Jeffrey Axler, Robert H. Riddell, Chen Zhu, A. M. Barrett, Enoch Bortey, William P. Forbes	7
2	Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension 2015 ·Journal of Palliative Medicine ·Janet Bull, Charles Wellman, Robert J. Israel, Andrew C. Barrett, Craig Paterson, William P. Forbes	57
3	Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain 2015 ·Journal of Pain Research ·Lynn R. Webster, Darren M. Brenner, A. P. Barrett, Craig Paterson, Enoch Bortey, William P. Forbes	17
4	Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis 2014 ·Alimentary Pharmacology & Therapeutics ·Jasmohan S. Bajaj, Andrew C. Barrett, Enoch Bortey, Craig Paterson, William P. Forbes	39
5	Long-term Safety and Tolerability of Once-daily Mesalamine Granules in the Maintenance of Remission of Ulcerative Colitis 2014 ·Inflammatory Bowel Diseases ·Gary R. Lichtenstein, Andrew C. Barrett, Enoch Bortey, Craig Paterson, William P. Forbes	7
6	Efficacy and Safety of Crofelemer for Noninfectious Diarrhea in HIV-Seropositive Individuals (ADVENT Trial): A Randomized, Double-Blind, Placebo-Controlled, Two-Stage Study 2013 ·HIV Clinical Trials ·Rodger D. MacArthur, Trevor Hawkins, Stephen J. Brown, Anthony LaMarca, Patrick G. Clay, Andrew C. Barrett, Enoch Bortey, Craig Paterson, Pamela L. Golden, William P. Forbes	29
7	Budesonide Foam for Inducing Remission in Active Mild-to-moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis: Results of Two Randomized, Placebo-controlled Trials 2013 ·The American Journal of Gastroenterology ·William J. Sandborn, Brian P. Bosworth, Salam Zakko, Glenn L. Gordon, Robert Rolleri, Jing Yu, Andrew C. Barrett, Enoch Bortey, Craig Paterson, William P. Forbes	0
8	Mesalazine granules 1.5 g once‐daily maintain remission in patients with ulcerative colitis who switch from other 5‐ ASA formulations: a pooled analysis from two randomised controlled trials 2012 ·Alimentary Pharmacology & Therapeutics ·Gary R. Lichtenstein, Salam Zakko, Glenn L. Gordon, Uma K. Murthy, Shahriar Sedghi, Robert E. Pruitt, Kunal Merchant, Enoch Bortey, William P. Forbes	8
9	195 RIFAXIMIN DECREASES VENOUS AMMONIA CONCENTRATIONS AND TIME-WEIGHTED AVERAGE AMMONIA CONCENTRATIONS CORRELATE WITH OVERT HEPATIC ENCEPHALOPATHY (HE) AS ASSESSED BY CONN SCORE IN A 6-MONTH STUDY 2010 ·Journal of Hepatology ·A. K. Sanyal, N M Bass, Fred Poordad, (unknown), K Mullen, Samuel H. Sigal, (unknown), Richard W. Brown, (unknown), Shahriar Sedghi, Kunal Merchant, (unknown), Audrey L. Shaw, Enoch Bortey, William P. Forbes	7
10	207 SAFETY OF RIFAXIMIN IN PATIENTS WITH HEPATIC ENCEPHALOPATHY: RESULTS OF A RANDOMIZED, PHASE 3, PLACEBO-CONTROLLED CLINICAL TRIAL 2009 ·Journal of Hepatology ·Kathleen Mullen, Samuel H. Sigal, Mahdi Sheikh, N M Bass, Fred Poordad, Kunal Merchant, Shirley Huang, (unknown), Enoch Bortey, William P. Forbes	4
11	The Effect of Multiple‐Dose, Oral Rifaximin on the Pharmacokinetics of Intravenous and Oral Midazolam in Healthy Volunteers 2007 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Helen S. Pentikis, (unknown), Carol Braun Trapnell, William P. Forbes, (unknown)	32
12	Effect of Cilostazol on Treadmill Walking, Community‐Based Walking Ability, and Health‐Related Quality of Life in Patients with Intermittent Claudication Due to Peripheral Arterial Disease: Meta‐Analysis of Six Randomized Controlled Trials 2002 ·Journal of the American Geriatrics Society ·Judith G. Regensteiner, John E. Ware, Walter J. McCarthy, Peter Zhang, William P. Forbes, (unknown), William R. Hiatt	170
13	Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication 2002 ·The American Journal of Cardiology ·Paul D. Thompson, (unknown), William P. Forbes, Peter Zhang	199
14	A comparison of cilostazol and pentoxifylline for treating intermittent claudication 2000 ·The American Journal of Medicine ·David L. Dawson, Bruce S. Cutler, William R. Hiatt, R W Hobson, John D. Martin, Enoch Bortey, William P. Forbes, D. Eugene Strandness	277
15	A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. 1999 ·PubMed ·Hugh G. Beebe, David L. Dawson, Bruce S. Cutler, (unknown), D. Eugene Strandness, Enoch Bortey, William P. Forbes	216
16	Effects of CYP3A Inhibition on the Metabolism of Cilostazol 1999 ·Clinical Pharmacokinetics ·Ajit Suri, William P. Forbes, Steven L. Bramer	33
17	Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cilostazol 1999 ·Clinical Pharmacokinetics ·Steven L. Bramer, William P. Forbes	18
18	Cilostazol Pharmacokinetics after Single and Multiple Oral Doses in Healthy Males and Patients with Intermittent Claudication Resulting from Peripheral Arterial Disease 1999 ·Clinical Pharmacokinetics ·Steven L. Bramer, William P. Forbes, Suresh Mallikaarjun	63
19	Relative Bioavailability and Effects of a High Fat Meal on Single Dose Cilostazol Pharmacokinetics 1999 ·Clinical Pharmacokinetics ·Steven L. Bramer, William P. Forbes	49
20	Pharmacokinetics of Multiple‐Dose Oral Cilostazol in Middle‐Age and Elderly Men and Women 1998 ·The Journal of Clinical Pharmacology ·Ajit Suri, William P. Forbes, Steven L. Bramer	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact